Catalyst Pharmaceuticals Investor Relations Material
Latest events
Q2 2024
Catalyst Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Catalyst Pharmaceuticals Inc
Access all reports
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. The company develops oral mid-kine receptor modulators for multiple indications for the treatment of neuromuscular weakness associated with amyotrophic lateral sclerosis. Catalyst Pharmaceuticals has a collaboration agreement with Memorial Sloan Kettering Cancer Center to develop drugs for muscle diseases associated with cancer or its treatment. It also develops a pipeline of compositions covering a range of applications including pain management, sleep disorders, and drug addiction.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
CPRX
Country
🇺🇸 United States